Predict your next investment

PhageTech company logo
HEALTHCARE | Biotechnology
phagetech.com

See what CB Insights has to offer

Founded Year

2014

Stage

Unattributed | Alive

Total Raised

$2.9M

Last Raised

$500K | 4 yrs ago

About PhageTech

PhageTech is a California based development stage company with a platform that employs a bacteriophage substrate for detecting analytes in urine, blood and most any other body fluid. This technology promises to offer equal or better performance against antibody based assays. With urine and other body fluids, it will not require any complex sample preparation or reagents and it can be run by minimally trained medical staff. Results are virtually instant and it can be implemented as a Point Of Care test. At the same time it is more robust, much less expensive to produce and scalable for large applications. Its shelf life will be measured in years (not months) and it will not require refrigeration for storage. These features give it many commercial advantages over current platforms.

PhageTech Headquarter Location

5 Mason #170

Irvine, California, 92618,

United States

949-377-0144

Latest PhageTech News

Mark IV Capital Co-leads $2.4M Series A for PhageTech

Oct 4, 2015

Mark IV Capital Co-leads $2.4M Series A for PhageTech 10/4/15 IRVINE, Calif.–(BUSINESS WIRE)–PhageTech, Inc. today announced that it has raised $2.4 million in Series A funding from a group of early stage investors co-led by Mark IV Capital and Black River Investments. Proceeds will be used to complete development and FDA clearance of its revolutionary PhageTech Biosensor™ technology. The closest thing to a cure for cancer is early detection. PhageTech Biosensors will enable early detection of cancers and other diseases while making disease detection instantaneous, simpler, affordable, near patient and readily accessible world-wide. CEO Richard Henson states, “Our technology enables an entire new category of near patient testing with tremendous benefits in portability, simplicity, time to result and cost over the current standard in lab-based diagnostics (e.g. sending samples out to a lab and waiting for results). The entire diagnostic test is contained in a chip the size of a postage stamp without compromising accuracy, enabling physicians to make instant treatment decisions. Our vision is to develop PhageTech Biosensors and readers for physicians as well as patients (e.g. through an app on a cell phone). It will especially have enormous implications for developing countries with minimal resources who are in need of simple, low cost, near patient testing. Our goal in 10 years is to touch over one billion people.” Developed with NIH funds at the University of California, Irvine, the PhageTech Biosensors will be interfaced with portable readers enabling inexpensive, quantitative, near patient testing in under one minute providing physicians with real-time valuable information for quicker diagnoses, treatment and improved patient outcomes. Mark IV Capital is a privately held investment firm founded in 1974. The company primarily acquires, invests in, develops, and manages commercial projects utilizing a long-term approach to deploy capital in markets where existing drivers will propel future value. As an investor, Mark IV Capital has invested in a wide variety of investment vehicles including funding real estate projects for developers; investing in hedge funds, venture capital funds, long equity funds; and providing direct equity to existing and start-up entities. Black River Investments, LLC provides private equity investments and is comprised of both operating and investment professionals experienced in helping companies expand their businesses. Stories you Need to Know Stories you Need to Know It's on us. Share your news here.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing PhageTech

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

PhageTech is included in 5 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

M

Medical Devices

7,873 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

B

Biopharmaceuticals

5,881 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

H

Health Monitoring & Diagnostics

3,094 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

PhageTech Patents

PhageTech has filed 1 patent.

The 3 most popular patent topics include:

  • Biosensors
  • Biotechnology
  • Electrochemistry
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/29/2019

Sensors, Biotechnology, Biosensors, Molecular biology, Electrochemistry

Application

Application Date

3/29/2019

Grant Date

Title

Related Topics

Sensors, Biotechnology, Biosensors, Molecular biology, Electrochemistry

Status

Application

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.